Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 0.7% – Still a Buy?

Posted by Stanley Muller on Jul 12th, 2026

Dogwood Therapeutics, Inc (NASDAQ:DWTX – Get Free Report)’s share price shot up 0.7% during mid-day trading on Friday . The company traded as high as $1.47 and last traded at $1.42. Approximately 40,106 shares were traded during trading, a decline of 62% from the average session volume of 105,357 shares. The stock had previously closed at $1.41.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Weiss Ratings lowered shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Dogwood Therapeutics in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Dogwood Therapeutics has an average rating of “Hold” and an average price target of $12.00.

Read Our Latest Research Report on DWTX

Dogwood Therapeutics Stock Up 0.7%

The stock’s 50 day moving average price is $1.61 and its 200-day moving average price is $2.38. The stock has a market capitalization of $47.75 million, a PE ratio of -0.13 and a beta of 1.70.

Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. On average, analysts forecast that Dogwood Therapeutics, Inc will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities & Exchange Commission. 9.05% of the stock is owned by institutional investors and hedge funds.

About Dogwood Therapeutics

(Get Free Report)

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.